IL300014A - Interaction of SARS-Cov-2 proteins through a molecular or cellular mechanism of host cells and compounds for the treatment of Covid-19 - Google Patents

Interaction of SARS-Cov-2 proteins through a molecular or cellular mechanism of host cells and compounds for the treatment of Covid-19

Info

Publication number
IL300014A
IL300014A IL300014A IL30001423A IL300014A IL 300014 A IL300014 A IL 300014A IL 300014 A IL300014 A IL 300014A IL 30001423 A IL30001423 A IL 30001423A IL 300014 A IL300014 A IL 300014A
Authority
IL
Israel
Prior art keywords
cov
sars
formulations
proteins
interaction
Prior art date
Application number
IL300014A
Other languages
English (en)
Hebrew (he)
Original Assignee
Akseera Pharma Corp
Merchant Shreema
Patel Manit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IN2021/050325 external-priority patent/WO2021199078A2/en
Application filed by Akseera Pharma Corp, Merchant Shreema, Patel Manit filed Critical Akseera Pharma Corp
Publication of IL300014A publication Critical patent/IL300014A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL300014A 2020-07-18 2021-07-19 Interaction of SARS-Cov-2 proteins through a molecular or cellular mechanism of host cells and compounds for the treatment of Covid-19 IL300014A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN202021030633 2020-07-18
IN202021054151 2020-12-12
PCT/IN2021/050325 WO2021199078A2 (en) 2020-03-29 2021-03-30 Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19.
PCT/IN2021/050699 WO2022018754A1 (en) 2020-07-18 2021-07-19 Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19.

Publications (1)

Publication Number Publication Date
IL300014A true IL300014A (en) 2023-03-01

Family

ID=79728594

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300014A IL300014A (en) 2020-07-18 2021-07-19 Interaction of SARS-Cov-2 proteins through a molecular or cellular mechanism of host cells and compounds for the treatment of Covid-19

Country Status (7)

Country Link
US (1) US20240024337A1 (https=)
EP (1) EP4181917A4 (https=)
JP (1) JP2023537229A (https=)
AU (1) AU2021313476A1 (https=)
CA (2) CA3179022A1 (https=)
IL (1) IL300014A (https=)
WO (1) WO2022018754A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4126913A4 (en) * 2020-03-29 2024-09-18 Akseera Pharma Corp. INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS OF HOST CELLS AND FORMULATIONS FOR THE TREATMENT OF COVID-19
AU2022204290A1 (en) * 2020-12-12 2023-07-27 Akseera Pharma Corp. Cannabidiol for augmenting vaccine mediated immunity and prophylaxis of covid-19
CA3255538A1 (en) * 2022-04-07 2023-10-12 Shreema DR. MERCHANT METHOD FOR USING CANNABIDIOL IN THE PREVENTION AND TREATMENT OF INTERFERON-SENSITIVE CONDITIONS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520684A (ja) * 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP4126913A4 (en) * 2020-03-29 2024-09-18 Akseera Pharma Corp. INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS OF HOST CELLS AND FORMULATIONS FOR THE TREATMENT OF COVID-19
WO2021209998A1 (en) * 2020-04-14 2021-10-21 Molad Ami Composition for the treatment of respiratory symptoms and methods thereof
US20230181484A1 (en) * 2020-05-11 2023-06-15 Add Advanced Drug Delivery Technologies Ltd. Uses and Formulations of Cannabinoids
US20230338396A1 (en) * 2020-05-14 2023-10-26 Augusta University Research Institute, Inc. Cannabidiol as a therapeutic modality for covid-19
CN120789031A (zh) * 2020-07-24 2025-10-17 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途

Also Published As

Publication number Publication date
US20240024337A1 (en) 2024-01-25
EP4181917A1 (en) 2023-05-24
CA3189802A1 (en) 2022-01-27
CA3179022A1 (en) 2021-10-07
EP4181917A4 (en) 2024-10-30
WO2022018754A1 (en) 2022-01-27
JP2023537229A (ja) 2023-08-31
AU2021313476A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
IL300014A (en) Interaction of SARS-Cov-2 proteins through a molecular or cellular mechanism of host cells and compounds for the treatment of Covid-19
CY1123676T1 (el) Συνθεσεις και μεθοδοι για την εσωτερικοποιηση ενζυμων
JOP20200307A1 (ar) جزيئات ربط ضد bcma واستخداماتها
WO2015031771A3 (en) Administration of kynurenine depleting enzymes for tumor therapy
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
CO7010783A2 (es) Proteína naglu humana recombinante y usos de la misma
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
MX2009000137A (es) Extractos de aphanizomenon flos aquae, y composiciones nutricionales, cosmeticas y farmaceuticas que contienen los mismos.
BR112021019109A2 (pt) Célula rpe manipulada, composições, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método para aplicar uma terapia com fvii
MX2016003943A (es) Composiciones y formulaciones para la prevencion y reduccion de tumorigenesis, invasion y proliferacion de celulas de cancer y metodos de produccion y uso en el tratamiento del cancer.
CL2022001655A1 (es) Variantes diseñadas de la alfa-glucosidasa ácida.
BR112012013868A8 (pt) composição, proteína de fusão, polinucleotídeo, vetor ou constructo de gene, célula hospedeira , composição farmacêutica, método in vitro e uso de uma composição.
WO2015031726A3 (en) Engineered primate l-methioninase for therapeutic purposes
WO2011097381A3 (en) Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof
ZA202006077B (en) Human kynureninase enzymes and uses thereof
WO2017151860A8 (en) Human kynureninase enzyme variants having improved pharmacological properties
BR112017013300A2 (pt) alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições.
BR112019000215A2 (pt) depleção de cistina mediada por enzima humana
EP4670724A3 (en) Anti-gprc5d monoclonal antibodies and uses thereof
WO2022184854A3 (en) Formulations of ace2 fc fusion proteins
SA523451188B1 (ar) شظية ربط مولد الضد مضادة لـليمفوبويتين الغدة الصعترية ذو ثبات محسن
CY1124679T1 (el) Μεθοδος μειωσης η απενεργοποιησης του ιικου και μικροβιακου περιεχομενου στις μεθοδους παρασκευης παγκρεατινης
MX386601B (es) Disminución de homocisteína mediada por enzimas humanas para el tratamiento de pacientes con hiperhomocisteinemia y homocistinuria.
GEP201706763B (en) Genetically stable oncolytic rna virus, method of manufacturing and use thereof
WO2024151745A3 (en) Targeted anti-prdm compositions and uses thereof